Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells

Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells

US Patent 12122850 · Granted Oct 22, 2024

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bispecific antibodies against CEACAM5 and CD472023
Bispecific antibodies against CEACAM5 and CD472023
Methods and compositions for diagnosis and treatment of disorders in patients wi2020
Methods and compositions for diagnosis and treatment of disorders in patients wi2017